Announcement of Availability for REGN5093

December 13, 2023

The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using REGN5093, a biparatopic, mesenchymal-epithelial transition (MET) receptor-targeting antibody, which is being developed by CTEP as an anticancer agent in collaboration with Regeneron. CTEP will also consider requests to supply REGN5093 for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical and/or clinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm).

All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.

If you are a DFHCC Investigator interested in submitting an LOI using REGN5093 through the ETCTN, please contact Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu)

Questions may be addressed to Dr. John J. Wright (wrightj@ctep.nci.nih.gov) Medical Officer, Investigational Drug Branch, CTEP, please CC Dr. Geoffrey Shapiro (geoffrey_shapiro@dfci.harvard.edu)